These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P; Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107 [TBL] [Abstract][Full Text] [Related]
3. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876 [TBL] [Abstract][Full Text] [Related]
4. ddI and d4T plus protease inhibitors. GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012 [TBL] [Abstract][Full Text] [Related]
5. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647 [TBL] [Abstract][Full Text] [Related]
6. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
7. New study shows efavirenz effective with d4T and 3TC. AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404 [TBL] [Abstract][Full Text] [Related]
8. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281 [TBL] [Abstract][Full Text] [Related]
9. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA; HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011 [TBL] [Abstract][Full Text] [Related]
10. Zidovudine and lamivudine: results of phase III studies. Staszewski S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914 [TBL] [Abstract][Full Text] [Related]
12. New questions about an old combination--ddI + d4T. Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675 [TBL] [Abstract][Full Text] [Related]
13. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P; J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288 [TBL] [Abstract][Full Text] [Related]
14. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. Fisher M AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718 [TBL] [Abstract][Full Text] [Related]
15. Merck protease inhibitor: more news from Retroviruses Conference. James JS AIDS Treat News; 1996 Feb; (no 241):1-3. PubMed ID: 11363186 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. Gulick R AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719 [TBL] [Abstract][Full Text] [Related]
17. Some competition for 1592. GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373 [TBL] [Abstract][Full Text] [Related]
18. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538 [TBL] [Abstract][Full Text] [Related]
19. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650 [TBL] [Abstract][Full Text] [Related]
20. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]